Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,641 to 1,660 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Cangrelor vs Clopidogrel: Incidence of Stent Thrombosis | 15 of 2,647 28 of 2,629 | -0.5 points -1.0 to -0.0 | 5,276 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of All-cause Mortality, MI, or IDR | 227 of 2,647 249 of 2,629 | -0.9 points -2.4 to 0.7 | 5,276 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of IDR | 37 of 2,647 46 of 2,629 | -0.4 points -1.0 to 0.3 | 5,276 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Genotype-Guided Therapy vs Conventional Therapy: Occurrence of the a Major Adverse Cardiovascular Event | 262 of 2,641 269 of 2,635 | -0.3 points -1.9 to 1.3 | 5,276 | NCT01742117 Tailored Antiplatelet Therapy Following PCI |
| Genotype-Guided Therapy vs Conventional Therapy: Thrombolysis in Myocardial Infarction Major or Minor Bleeding | 54 of 2,641 53 of 2,635 | 0.0 points -0.7 to 0.8 | 5,276 | NCT01742117 Tailored Antiplatelet Therapy Following PCI |
| Genotype-Guided Therapy vs Conventional Therapy: deaths from any cause | 95 of 2,641 98 of 2,635 | -0.1 points -1.1 to 0.9 | 5,276 | NCT01742117 Tailored Antiplatelet Therapy Following PCI |
| Experimental Group vs Control Group: deaths from any cause | 23 of 476 209 of 4,793 | 0.5 points -1.2 to 2.8 | 5,269 | NCT02694185 Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications |
| High Dose Influenza Vaccine vs Standard Dose Influenza Vaccine: deaths from any cause | 223 of 2,630 222 of 2,630 | 0.0 points -1.5 to 1.5 | 5,260 | NCT02787044 INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure |
| Cangrelor vs Clopidogrel: Incidence of All-cause Mortality | 94 of 2,628 113 of 2,618 | -0.7 points -1.8 to 0.3 | 5,246 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One MAE From Birth to Day 366 Post-birth | 2,706 of 3,494 1,330 of 1,741 | 1.1 points -1.3 to 3.5 | 5,235 | NCT04605159 A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers |
| RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One Serious Adverse Event (SAE) From Birth to Day 181 Post-birth | 640 of 3,494 323 of 1,741 | -0.2 points -2.5 to 2.0 | 5,235 | NCT04605159 A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers |
| RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One Adverse Event (AE) Leading to Study Withdrawal From Birth to Day 181 Post-birth | 19 of 3,494 4 of 1,741 | 0.3 points -0.1 to 0.6 | 5,235 | NCT04605159 A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers |
| RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One AE Leading to Study Withdrawal From Birth to Day 366 Post-birth | 21 of 3,494 4 of 1,741 | 0.4 points -0.0 to 0.7 | 5,235 | NCT04605159 A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers |
| RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One SAE From Birth to Day 366 Post-birth | 731 of 3,494 371 of 1,741 | -0.4 points -2.8 to 1.9 | 5,235 | NCT04605159 A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers |
| RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One Medically Attended AE (MAE) From Birth to Day 181 Post-birth | 2,321 of 3,494 1,135 of 1,741 | 1.2 points -1.5 to 4.0 | 5,235 | NCT04605159 A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers |
| Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Cognitive Decline | 230 of 2,642 192 of 2,589 | 1.3 points -0.2 to 2.8 | 5,231 | NCT00153101 Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. |
| High Dose Influenza Vaccine vs Standard Dose Influenza Vaccine: serious adverse events | 2 of 2,606 4 of 2,604 | -0.1 points -0.3 to 0.1 | 5,210 | NCT02787044 INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure |
| AndroGel 1.62% vs Placebo: Time From Randomization to First Clinical Fracture: Number and Percentage of Participants With an Event | 91 of 2,601 64 of 2,603 | 1.0 points 0.1 to 2.0 | 5,204 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| CT Colonography vs Colonoscopy: serious adverse events | 0 of 2,600 1 of 2,600 | -0.0 points -0.2 to 0.1 | 5,200 | NCT00084929 The National CT Colonography Trial |
| AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Heart Failure | 55 of 2,596 50 of 2,602 | 0.2 points -0.6 to 1.0 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=83
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00385138-48978c40",
"title": "Cangrelor vs Clopidogrel: Incidence of Stent Thrombosis",
"summary": "15 of 2647 against 28 of 2629; risk difference -0.5 points, 95% interval -1.0 to -0.0; NCT00385138, Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.",
"record": "/library/comparisons/NCT00385138-48978c40",
"nct_id": "NCT00385138",
"kind": "outcome",
"participants": 5276,
"risk_difference": {
"value": -0.004983644833289097,
"lower": -0.010185167602418293,
"upper": -0.00007293653237660808
},
"group_1": "15 of 2,647",
"group_2": "28 of 2,629",
"difference": "-0.5 points",
"interval": "-1.0 to -0.0",
"trial_title": "Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition."
},
{
"id": "NCT00385138-4abdff99",
"title": "Cangrelor vs Clopidogrel: Incidence of All-cause Mortality, MI, or IDR",
"summary": "227 of 2647 against 249 of 2629; risk difference -0.9 points, 95% interval -2.4 to 0.7; NCT00385138, Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.",
"record": "/library/comparisons/NCT00385138-4abdff99",
"nct_id": "NCT00385138",
"kind": "outcome",
"participants": 5276,
"risk_difference": {
"value": -0.00895535728527369,
"lower": -0.02446565528418624,
"upper": 0.006527260042186204
},
"group_1": "227 of 2,647",
"group_2": "249 of 2,629",
"difference": "-0.9 points",
"interval": "-2.4 to 0.7",
"trial_title": "Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition."
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=84",
"request_id": "ybFa20mjjb5UMELi"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant